0001209191-24-005154.txt : 20240401 0001209191-24-005154.hdr.sgml : 20240401 20240401190013 ACCESSION NUMBER: 0001209191-24-005154 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240328 FILED AS OF DATE: 20240401 DATE AS OF CHANGE: 20240401 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wills Robert James CENTRAL INDEX KEY: 0001634189 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50549 FILM NUMBER: 24811670 MAIL ADDRESS: STREET 1: 175 TOYOTA PLAZA, 7TH FLOOR CITY: MEMPHIS STATE: TN ZIP: 38103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oncternal Therapeutics, Inc. CENTRAL INDEX KEY: 0001260990 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 621715807 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12230 EL CAMINO REAL STREET 2: SUITE 230 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 434-1113 MAIL ADDRESS: STREET 1: 12230 EL CAMINO REAL STREET 2: SUITE 230 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: GTX INC /DE/ DATE OF NAME CHANGE: 20030822 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-03-28 0 0001260990 Oncternal Therapeutics, Inc. ONCT 0001634189 Wills Robert James 12230 EL CAMINO REAL, SUITE 230 SAN DIEGO CA 92130 1 0 0 0 0 Common Stock 2024-03-28 4 P 0 6914 8.4759 A 6914 D The Reporting Person's common stock purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 980 shares at a weighted average price per share of $8.1548, with the sale of 980 shares of common stock at a price per share of $9.04 on February 23, 2024. The Reporting Person has agreed to pay the issuer $867.51, representing the full amount of the profit realized in connection with the short-swing transaction. The reported price is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $8.095 to $9.00. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the range set forth above. /s/Chase C. Leavitt, Attorney-in-fact 2024-04-01